{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:49:10Z","timestamp":1779306550923,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-019-1407-2","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T07:02:36Z","timestamp":1565334156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data"],"prefix":"10.1186","volume":"19","author":[{"given":"Tim","family":"Sinnecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrie","family":"Hadisurya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman","family":"Schneider-Hohendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Wrede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Gembruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pilgram-Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ortwin","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-3621","authenticated-orcid":false,"given":"Markus","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"issue":"20","key":"1407_CR1","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","volume":"90","author":"JR Berger","year":"2018","unstructured":"Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90(20):e1815\u2013e21.","journal-title":"Neurology."},{"issue":"14","key":"1407_CR2","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1177\/1352458513510224","volume":"19","author":"MP Wattjes","year":"2013","unstructured":"Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013;19(14):1826\u201340.","journal-title":"Mult Scler"},{"key":"1407_CR3","doi-asserted-by":"publisher","unstructured":"Lohmann L, Janoschka C, Schulte-Mecklenbeck A, Klinsing S, Kirstein L, Hanning U, et al. Immune cell profiling during switching from Natalizumab to Fingolimod reveals differential effects on systemic immune-regulatory networks and on trafficking of non-T cell populations into the cerebrospinal fluid\u2014results from the ToFingo successor study. Front Immunol. 2018;9.9:1560. \n                    https:\/\/doi.org\/10.3389\/fimmu.2018.01560\n                    \n                  . eCollection 2018.","DOI":"10.3389\/fimmu.2018.01560"},{"key":"1407_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12974-015-0365-x","volume":"12","author":"M Spadaro","year":"2015","unstructured":"Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. J Neuroinflammation. 2015;12:146.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"1407_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","volume":"78","author":"N Schwab","year":"2012","unstructured":"Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control. Neurology. 2012;78(7):458\u201367 discussion 65.","journal-title":"Neurology"},{"issue":"16","key":"1407_CR6","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1212\/WNL.0000000000002586","volume":"86","author":"J Hodel","year":"2016","unstructured":"Hodel J, Darchis C, Outteryck O, Verclytte S, Deramecourt V, Lacour A, et al. Punctate pattern: a promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology. 2016;86(16):1516\u201323.","journal-title":"Neurology."},{"issue":"6","key":"1407_CR7","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1212\/NXI.0000000000000171","volume":"2","author":"T Sinnecker","year":"2015","unstructured":"Sinnecker T, Othman J, Kuhl M, Mekle R, Selbig I, Niendorf T, et al. 7T MRI in natalizumab-associated PML and ongoing MS disease activity: a case study. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e171.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"1407_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1212\/WNL.0b013e3182648bc8","volume":"79","author":"T Sinnecker","year":"2012","unstructured":"Sinnecker T, Dorr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology. 2012;79(7):708\u201314.","journal-title":"Neurology."},{"issue":"1","key":"1407_CR9","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1212\/NXI.0000000000000415","volume":"5","author":"S Nishiyama","year":"2018","unstructured":"Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, Takai Y, et al. Fingolimod-associated PML with mild IRIS in MS: a clinicopathologic study. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e415.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"1407_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/1352458515608961","volume":"22","author":"EE Longbrake","year":"2016","unstructured":"Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler. 2016;22(8):1061\u201370.","journal-title":"Mult Scler"},{"issue":"3","key":"1407_CR11","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","volume":"2","author":"CM Spencer","year":"2015","unstructured":"Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BAC, Zamvil SS. Reduction of CD8 +T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurology\u00ae neuroimmunology Neuroinflammation. 2015;2(3):e76.","journal-title":"Neurology\u00ae neuroimmunology Neuroinflammation"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1407-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1407-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1407-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T19:11:19Z","timestamp":1596827479000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1407-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1407-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9433\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9433\/v2","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"9 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the local university (Duisburg-Essen) institutional review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images and videos. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tim Sinnecker has received travel support from Roche and Actelion, and is employee of the Medical Image Analysis Center in Basel, Switzerland.Jeffrie Hadisurya has received travel funding from Novartis, Teva, Bayer and Biogen.Tilman Schneider-Hohendorf has received research and travel support from Biogen and Novartis.Nicholas Schwab has received travel funding from Novartis, and Biogen.Karsten Wrede reports no disclosures.Oliver Gembruch reports no disclosures.Ralf Gold received speaker\u2019s and board honoraria from Baxter, Bayer Schering, Biogen Idec, CLB Behring, Genzyme, Merck Serono, Novartis, Roche, Stendhal, Talecris, TEVA. His department received grant support from Bayer Schering, BiogenIdec, Genzyme, Merck Serono, Novartis, TEVA. He possesses stock options from Merck Serono and Roche.Kerstin Hellwig reports grants and honoriaria from Biogen, Novartis, Roche, Bayer Healthcare, Teva, Sanofi and Merck.Sara Pilgram-Pastor reports no disclosures.Ortwin Adams reports no disclosures.Philipp Albrecht reports grants, personal fees and non-financial support from Allergan, Biogen, Ipsen, Merz Pharmaceuticals, Novartis, and Roche, personal fees and non-financial support from Bayer Healthcare, and Merck, and non-financial support from Sanofi-Aventis\/Genzym.Hans-Peter Hartung has received fees for serving on steering commitees from Biogen Idec, GeNeuro, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, MedImmune, Bayer HealthCare, Forward Pharma, and Roche, fees for serving on advisory boards from Biogen Idec, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, and Roche, and lecture fees from Biogen Idec, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, MedImmune, and Roche.Orhan Aktas has received, with approval by the Heinrich Heine University, advisor fees or honoraria from Almirall, Bayer HealthCare, Biogen, MedImmune, Merck, Novartis, and Teva; research support from Bayer HealthCare, Biogen, Novartis, Roche, and Teva.Markus Kraemer has received, by approval by his hospital, honoria from Bayer Schering, Biogen Idec, Merck Pharma Novartis Pharma, Teva Pharma, Roche Pharma und Shire Deutschland.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}